Sirolimus Patent Expiration
Sirolimus is used for treating locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PECOMA) in adults. It was first introduced by Pf Prism Cv
Sirolimus Patents
Given below is the list of patents protecting Sirolimus, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fyarro | US11497737 | Pharmaceutical compositions of albumin and rapamycin | Oct 28, 2040 | Aadi Sub |
| Fyarro | US10973806 | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin | Jun 29, 2036 | Aadi Sub |
| Fyarro | US12133844 | Methods of treating epithelioid cell tumors | Jun 29, 2036 | Aadi Sub |
| Fyarro | US10705070 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Mar 05, 2036 | Aadi Sub |
| Fyarro | US12061183 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Mar 05, 2036 | Aadi Sub |
| Fyarro | US10206887 | Prion free nanoparticle compositions and methods of making thereof | Apr 15, 2030 | Aadi Sub |
| Fyarro | US8911786 | Nanoparticle comprising rapamycin and albumin as anticancer agent | Feb 14, 2029 | Aadi Sub |
| Rapamune |
US5989591 (Pediatric) | Rapamycin formulations for oral administration |
Sep 11, 2018
(Expired) | Pf Prism Cv |
| Rapamune | US5989591 | Rapamycin formulations for oral administration |
Mar 11, 2018
(Expired) | Pf Prism Cv |
| Rapamune |
US5536729 (Pediatric) | Rapamycin formulations for oral administration |
Mar 30, 2014
(Expired) | Pf Prism Cv |
| Rapamune |
US5100899 (Pediatric) | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan 07, 2014
(Expired) | Pf Prism Cv |
| Rapamune | US5536729 | Rapamycin formulations for oral administration |
Sep 30, 2013
(Expired) | Pf Prism Cv |
| Rapamune | US5100899 | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul 07, 2013
(Expired) | Pf Prism Cv |
| Rapamune |
US5403833 (Pediatric) | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct 04, 2012
(Expired) | Pf Prism Cv |
Sirolimus's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List